PHASE III CASPIAN TRIAL
OF DURVALUMAB IN 1st LINE ES-SCLC

PATIENTS
with previously untreated extensive-stage small cell lung cancer (ES-SCLC)

During chemotherapy (EP)
- D+T+EP (carbo or cis)
  4 cycles every 3 weeks
- D+EP (carbo or cis)
  4 cycles every 3 weeks
- EP (carbo or cis)
  Up to 6 cycles every 3 weeks

Post-chemotherapy
- D every 4 weeks until progression*
- D every 4 weeks until progression*
- D every 4 weeks until progression*

PCI (optional)

Primary endpoints
- OS vs EP
- OS vs EP
- OS vs EP

Key Trial Characteristics
- Control arm reflects real-world design with up to 6 cycles of EP and optional PCI
- Flexibility of platinum-based regimens

*or other discontinuation criteria are met

For use with healthcare-oriented media and patient advocacy groups only | US-32095 Last Updated 9/19